692 reports of this reaction
3.5% of all TOBRAMYCIN SOLUTION reports
#2 most reported adverse reaction
PNEUMONIA is the #2 most commonly reported adverse reaction for TOBRAMYCIN SOLUTION, manufactured by Amneal Pharmaceuticals LLC. There are 692 FDA adverse event reports linking TOBRAMYCIN SOLUTION to PNEUMONIA. This represents approximately 3.5% of all 19,799 adverse event reports for this drug.
Patients taking TOBRAMYCIN SOLUTION who experience pneumonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PNEUMONIA is moderately reported among TOBRAMYCIN SOLUTION users, representing a notable but not dominant share of adverse events.
In addition to pneumonia, the following adverse reactions have been reported for TOBRAMYCIN SOLUTION:
The following drugs have also been linked to pneumonia in FDA adverse event reports:
PNEUMONIA has been reported as an adverse event in 692 FDA reports for TOBRAMYCIN SOLUTION. This does not prove causation, but indicates an association observed in post-market surveillance data.
PNEUMONIA accounts for approximately 3.5% of all adverse event reports for TOBRAMYCIN SOLUTION, making it one of the most commonly reported side effect.
If you experience pneumonia while taking TOBRAMYCIN SOLUTION, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.